[Skip to Content]
[Skip to Content Landing]
Views 62
Citations 0
Comment & Response
September 6, 2018

Information Transparency in the Drug Approval Process

Author Affiliations
  • 1Oncologic Drugs Advisory Committee, Food and Drug Administration, Washington, DC
  • 2Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
  • 3Dana-Farber Cancer Institute, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 4Duke Cancer Institute, Durham, North Carolina
JAMA Oncol. Published online September 6, 2018. doi:10.1001/jamaoncol.2018.4143

To the Editor Drs Gyawali and Goldstein1 recently published a Viewpoint in which they accuse the US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) of being ignorant of overall survival (OS) data from the S-TRAC adjuvant sunitinib trial, and that this ignorance led to a recommendation for approval from 6 ODAC members and subsequently the FDA. They further accuse the sponsor of hiding the OS data in the Supplement of the full publication.2

First Page Preview View Large
First page PDF preview
First page PDF preview